Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Packaging: Sterile sealed vial
Formulated to support workout energy, focus and training performance
That is 4mg wasted
REDEFINE-1: Phase 3 Pivotal Trial (NCT05064293) Study Title: "Efficacy and Safety of CagriSema in Adults With Overweight or Obesity (REDEFINE 1)" Status: Completed (Results Published 2024) Phase: Phase 3 Enrollment: 3,400+ participants Study Period: 2021-2024 Location: Global, 15+ countries Design: Randomized, double-blind, active-controlled Duration: 68 weeks Intervention: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs
US$ 28.99
US$ 26.42
US$ 24.19
US$ 20.19
US$ 23.79
US$ 21.72
US$ 27.17
US$ 26.93
US$ 22.44
US$ 28.54
US$ 28.71
US$ 25.02
